Six-month post-discharge follow-up of clinical outcomes and costs for apheresis therapies in COVID-19 survivors, finding limited long-term cost-effectiveness.
Comparative analysis of plasmapheresis and hemoperfusion for managing cytokine release syndrome in critically ill COVID-19 patients.